AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05168397 — intervention group
Intervention type: OTHER
Intervention: RV4857A
Description: RV4857A formula CD2110 is a sunscreen product
Study NCT01776320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
Study NCT03087890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole
Description: Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
Study NCT03087890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2 tablets placebo daily for 48 weeks
Study NCT01187368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVAHEART Left Ventricular Assist System (LVAS)
Description: Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
Study NCT01187368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate 3
Description: Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
Study NCT02578680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV infusion
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT02578680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study NCT02578680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study NCT02578680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study NCT02578680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study NCT02578680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: IV infusion
Study NCT02879591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Social Skills training with Avatar therapist
Study NCT02879591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Skills training with Avatar therapist
Study NCT03300817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03300817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 Peptide-Poly-ICLC Vaccine
Description: Given SC
Study NCT03290417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 5000 IU/cap; One cap by mouth daily
Study NCT03290417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 720 mg/cap; one capsule by mouth 3 times per day
Study NCT03290417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: 250mg/cap; two capsules by mouth 4 times per day
Study NCT04494347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MitraClip TMVR and Watchman LAAO
Description: The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
Study NCT00697866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 3 consecutive lots; 3-dose intramuscular injection
Study NCT00697866 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study NCT00549900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
Description: Intramuscular injection, 3 doses
Study NCT02918396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scar-Based Radio-frequency Ablation
Description: Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as \<0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
Study NCT02918396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotor Anchors Radio-frequency Ablation
Description: Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
Study NCT02918396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PVI by Radio-frequency Ablation
Description: Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
Study NCT04015609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaning Centered Psychotherapy for Latinos
Description: MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
Study NCT04015609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy for Latinos
Description: MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
Study NCT04015609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
Description: Determines the degree of spiritual well-being
Study NCT04015609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
Description: Determines the degree of spiritual well-being
Study NCT04015609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
Description: Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
Study NCT04015609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
Description: Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
Study NCT04015609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-assessment questionnaire
Description: Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
Study NCT04015609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-assessment questionnaire
Description: Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
Study NCT03047356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: If-then plans
Description: If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)
Study NCT03047356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
Study NCT04177485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS text reminders
Description: SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
Study NCT03812653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
Study NCT00925912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perianal block
Description: 0.25% bupivacaine injected at perianal region
Study NCT00727181 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trifecta aortic heart valve
Description: Replacement of a diseased, damaged, or malfunctioning aortic heart valve
Study NCT00195403 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Etanercept 25mg Injection, 2 times/week
Study NCT00686465 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET/CT scan
Description: Patients will undergo whole body FDG-PET/CT imaging
Study NCT04449952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint
Description: Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
Study NCT00166114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
Study NCT00166114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: 25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
Study NCT00460408 — intervention group
Intervention type: DRUG
Intervention: Macugen
Description: Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
Study NCT04449952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% Hydroalcohol Mouth Rinse
Description: Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
Study NCT02683174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel ambulatory patch (ZIO® XT Patch)
Description: All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
Study NCT02683174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNP and hs-troponin I at 0 and 3 hours post ED attendance
Description: All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
Study NCT04574206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elaborative Reminiscence (ER)
Description: Parents will be trained to use elaborative communication techniques in conversations with their child.
Study NCT04574206 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Present Tense Talk (PTT)
Description: Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
Study NCT00123409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone disease management
Description: Telephone based care management
Study NCT00123409 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care
Study NCT02705976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
Study NCT02705976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
Study NCT02930317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (50 IU/kg)
Study NCT02930317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (On-demand treatment)
Study NCT01824225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Study NCT03944200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01(A), Sugamet SR Tab 5/1000mg®
Description: Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
Study NCT03944200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)
Description: Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
Study NCT02798653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choriomon® injection
Description: Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
Study NCT02798653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choriomon® injection+Endometrin ®
Description: Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
Study NCT02798653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin ® vaginal tablets
Description: Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
Study NCT03098589 — intervention group
Intervention type: DRUG
Intervention: Revlimid
Description: Revlimid
Study NCT00610558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 1: Juvenile Myoclonic Epilepsy
Description: Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
Study NCT00610558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 2: Frontal Lobe Epilepsy
Description: Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
Study NCT00610558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 3: Normal Controls
Description: Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
Study NCT03770520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QFR-guided CABG
Description: CABG surgery based on CAG and QFR
Study NCT03770520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided CABG
Description: CABG surgery based on heart team discussion of CAG
Study NCT02895659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)
Description: Perioperative hemodynamic management will be performed according to a specified treatment protocol.
Study NCT02121392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Nerve Block Catheter
Description: ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
Study NCT02121392 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Adductor Canal Nerve Block Sham Catheter
Description: Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
Study NCT04449952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
Study NCT04449952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula
Description: Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
Study NCT04449952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush teeth at least one minute with provided bristled toothbrush.
Study NCT04449952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint Floss
Description: Participants will use marketed fluoride-containing dentifrice, floss.
Study NCT02346331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO algorithm of fluid boluses guided by physical examination
Study NCT02346331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequent patient monitoring
Description: Vital signs and physical exam every 30-60 minutes
Study NCT02346331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early administration of empiric antibiotics
Description: Clinician will be prompted to administer antibiotics within 60 minutes
Study NCT02346331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen delivery
Study NCT02346331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction of hypoglycemia
Description: If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered